In preparation for the full opening of the Quadram Institute in mid-2018, the Institute of Food Research (IFR) has become Quadram Institute Bioscience. Its company number remains the same as does the registered office until it moves to the new building mid-2018.
Opening in 2018, the Quadram Institute will be at the forefront of a new interface between food science, gut biology and health, developing solutions to worldwide challenges in food-related disease and human health.
The Quadram Institute will bring together research teams from Quadram Institute Bioscience, with others from the University of East Anglia’s Faculty of Science and Norwich Medical School, as well as the Norfolk and Norwich University Hospitals’ regional gastrointestinal endoscopy unit.
The institute will have the capacity for 300 research staff and a further 100 staff supporting one of Europe’s largest endoscopy facilities. It will be engaged in fundamental and translational food and health research, alongside clinical studies, endoscopy and industry, working together to become a leading international hub for food and health research, combining scientific excellence and clinical expertise, delivering impacts on patient care and accelerating innovation.
Establishing the Quadram Institute maximises the impact of the unique world-class bioscience cluster based at the Norwich Research Park, including the excellent plant and microbial science at the John Innes Centre and computational science and sequencing expertise at the Earlham Institute.
Ian Charles is the Director of Quadram Institute Bioscience and leads the programme to develop the UK’s new Quadram Institute, based at the Norwich Research Park.
Professor Charles returned to the UK in 2015 from Australia where he was Director of the ithree institute, University of Technology, Sydney. He has over 30 years’ experience in academic and commercial research. His academic career has included being a founding member of The Wolfson Institute for Biomedical Research at University College London, one the UK’s first institutes of translational medicine. He has also worked in the pharmaceutical industry at Glaxo Wellcome, and has been founder and CSO of biotech companies in the area of infectious disease, including Arrow Therapeutics, sold to AstraZeneca, and Auspherix a venture capital backed company founded in 2013. His current research interests include infectious diseases as well as the microbiome and its impact on health and wellbeing.